Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis
Key Highlights
- ➤Abbott initiated VOYAGER CE trial for investigational Encantor TAVI system
- ➤VOYAGER CE will enroll up to 300 patients across Europe and Australia
- ➤Study will support potential CE Mark approval for Encantor in Europe
- ➤Abbott plans to initiate a pivotal U.S. trial in coming months
- ➤Six-month Encantor feasibility data will be presented Nov. 22 at PCR London Valves 2026
Expert Statements
Didier Tchétché, Director of the structural heart disease department, Clinique Pasteur, Toulouse, France, and co-principal investigator of VOYAGER CE
“TAVI has transformed the treatment of severe aortic stenosis, but physicians continue to seek technologies that make procedures more predictable and allow treatment to be tailored to individual patients”
Didier Tchétché, Director of the structural heart disease department, Clinique Pasteur, Toulouse, France, and co-principal investigator of VOYAGER CE
“Encantor's balloon-expandable design and software-guided approach are intended to give physicians greater control and procedural confidence.”
Sandra Lesenfants, Senior vice president of Abbott's structural heart business
“Our ambition is to give physicians the right technology for each patient”
Sandra Lesenfants, Senior vice president of Abbott's structural heart business
“Our investigational Encantor system complements our Navitor self-expanding platform with a balloon-expandable option designed around physician insights, precise deployment and procedural ease of use. Advancing VOYAGER CE brings us another step closer to offering physicians a broader portfolio of structural heart solutions.”
Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis PR Newswire
* Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve performance * Encantor early feasibility study data will be presented at PCR London Valves 2026 ABBOTT PARK, Ill., Nov. 19, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has initiated the VOYAGER CE clinical trial evaluating the safety and efficacy of its investigational Encantor™ transcatheter aortic valve implantation (TAVI) software-guided balloon-expandable system for treating symptomatic severe aortic stenosis. The first enrollment in the VOYAGER CE study occurred at Macquarie University in Sydney, Australia, led by Stephen Worthley, M.B.B.S, Ph.D.
Get started
Create a free account to read the full story.
